Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:30 AM
Ignite Modification Date:
2025-12-25 @ 2:30 AM
NCT ID:
NCT03294434
Eligibility Criteria:
Inclusion Criteria:
* Have given written informed consent to participate
* Assessed by a neuroscience MDT to have a high grade glioma on imaging, OR if in the opinion of the CI, with guidance from the local PI that all relevant and appropriate members of a multidisciplinary team agree a high grade glioma diagnosis;
* Considered suitable for radical radiotherapy (60 Gy) with concomitant chemotherapy (Stupp Regime);
* WHO PS 0 or 1 (see Appendix 3);
* Age ≥16;
* Patient suitable for tumour resection where the treating neurosurgeon feels that \>90% of the enhancing tumour will be resected;
Exclusion Criteria:
* Patients who are participating in trials involving investigational treatments
* Patients who are unsuitable for a contrast-enhanced MRI will be excluded. Such clinical problems include, but are not limited to:
* MR unsafe metallic implants;
* Claustrophobia;
* Allergy to gadolinium contrast agent;
* History of severe renal impairment.
* Patients unable to provide written informed consent
* PET sub-study only: Pregnant women
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
16 Years
Study:
NCT03294434
Study Brief:
Protocol Section:
NCT03294434